Analysts Anticipate Kala Pharmaceuticals (KALA) to Announce -$0.44 EPS

Wall Street analysts expect Kala Pharmaceuticals (NASDAQ:KALA) to announce earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kala Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.41). The company is expected to issue its next earnings results on Monday, June 25th.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.20) to ($1.74). For the next financial year, analysts expect that the company will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.96) to ($1.93). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Kala Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Monday, March 26th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.09).

Several research firms recently commented on KALA. BidaskClub raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Wells Fargo reaffirmed an “outperform” rating and set a $19.00 target price (down from $24.00) on shares of Kala Pharmaceuticals in a report on Thursday, January 25th. They noted that the move was a valuation call. Finally, Wedbush reaffirmed an “outperform” rating and set a $46.00 target price on shares of Kala Pharmaceuticals in a report on Friday, December 22nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $35.80.

Kala Pharmaceuticals stock traded down $0.21 during midday trading on Tuesday, hitting $16.41. 74,303 shares of the company were exchanged, compared to its average volume of 224,987. The firm has a market cap of $402.96 and a price-to-earnings ratio of -2.81. Kala Pharmaceuticals has a fifty-two week low of $11.81 and a fifty-two week high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14.

In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc purchased 170,338 shares of the stock in a transaction on Wednesday, January 10th. The shares were bought at an average price of $12.83 per share, for a total transaction of $2,185,436.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired 1,108,150 shares of company stock worth $15,772,394 in the last quarter.

Hedge funds have recently modified their holdings of the business. Orbimed Advisors LLC purchased a new position in Kala Pharmaceuticals during the third quarter worth approximately $54,251,000. JPMorgan Chase & Co. purchased a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $4,037,000. Bank of New York Mellon Corp purchased a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $540,000. Crestline Management LP purchased a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $888,000. Finally, Farallon Capital Management LLC lifted its position in shares of Kala Pharmaceuticals by 85.0% in the fourth quarter. Farallon Capital Management LLC now owns 185,000 shares of the company’s stock valued at $3,421,000 after acquiring an additional 85,000 shares in the last quarter. Institutional investors own 72.39% of the company’s stock.

WARNING: “Analysts Anticipate Kala Pharmaceuticals (KALA) to Announce -$0.44 EPS” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3341325/analysts-anticipate-kala-pharmaceuticals-kala-to-announce-0-44-eps.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease.

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Comparing Clean Energy Fuels  & UGI
Comparing Clean Energy Fuels & UGI
Head to Head Comparison: Avinger  vs. Its Competitors
Head to Head Comparison: Avinger vs. Its Competitors
Comparing Quest Diagnostics  & Biocept
Comparing Quest Diagnostics & Biocept
Reviewing Destiny Media Tech  and eGain
Reviewing Destiny Media Tech and eGain
Topaz Coin  Tops 24-Hour Volume of $0.00
Topaz Coin Tops 24-Hour Volume of $0.00
Cannation Reaches Market Capitalization of $81,370.00
Cannation Reaches Market Capitalization of $81,370.00


© 2006-2018 Ticker Report. Google+.